RESEARCH ARTICLE |
|
Year : 2012 | Volume
: 44
| Issue : 6 | Page : 732-736 |
Shatavarins (containing Shatavarin IV) with anticancer activity from the roots of Asparagus racemosus
Shankar K Mitra1, Neswi S Prakash2, Ramachandran Sundaram2
1 Rajiv Gandhi University of Health Sciences, 4th "T" Block, Jayanagar, Bangalore, Karnataka, India 2 R & D Center, The Himalaya Drug Company, Makali, Bangalore, Karnataka, India
Correspondence Address:
Neswi S Prakash R & D Center, The Himalaya Drug Company, Makali, Bangalore, Karnataka India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.103273
Objectives: The anticancer activity of shatavarins (containing shatavarin IV) isolated from the roots of Asparagus racemosus (Wild) was evaluated using in vitro and in vivo experimental models.
Material and Methods: The shatavarin IV was isolated from ethyl acetate insoluble fraction (AR-2B) of chloroform:methanol (2:1) (AR-2) extract of A. racemosus roots. The cytotoxicity (in vitro) of shatavarin IV and other shatavarins rich fraction was carried out using of MTT assay using MCF-7 (human breast cancer), HT-29 (human colon adenocarcinoma), and A-498 (human kidney carcinoma) cell lines. The in vivo anticancer activity of shatavarins (containing shatavarin IV) was evaluated against Ehrlich ascites carcinoma (EAC) tumor bearing mice.
Results: The isolated shatavarin IV (84.69 %) along with shatavarins rich fraction, coded AR-2B containing 5.05% shatavarin IV showed potent cytotoxicity. Oral administration of AR-2B to tumor bearing mice at doses of 250 and 500 mg/kg body weight for 10 days, showed significant reduction in percent increase in body weight, tumor volume, packed cell volume, viable tumor cell count, and increased non-viable cell count when compared to the untreated mice of the EAC control group. The restoration of hematological parameters towards normalcy was also observed.
Conclusion: The result suggests that the shatavarins (containing shatavarin IV) rich fraction (AR-2B) exhibits significant anticancer activity in both in vitro and in vivo experimental models.
[FULL TEXT] [PDF]*
|